1. Khodaverdi E, Golmohammadian A, Mohajeri SA, Zohuri G, Mirzazadeh Tekie FS, Hadizadeh F. Biodegradable in situ gel-forming controlled drug delivery system based on thermosensitive poly (-caprolactone)-poly (ethylene glycol)-poly (-caprolactone) hydrogel. ISRN Pharm. 2012; 2012:976879.
2. Abdollahiyan P, Oroojalian F, Mokhtarzadeh A, de la Guardia M. Hydrogel‐based 3D bioprinting for bone and cartilage tissue engineering. Biotechnol J 2020;15:2000095.
3. Pourpirali R, Mahmoudnezhad A, Oroojalian F, Zarghami N, Pilehvar-Soltanahmadi Y. Prolonged proliferation and delayed senescence of the adipose-derived stem cells grown on the electrospun composite nanofiber co-encapsulated with TiO2 nanoparticles and metformin-loaded mesoporous silica nanoparticles. Int J Pharm 2021; 604:120733.
4. Hosseini SA, Mohammadi R, Noruzi S, Ganji R, Oroojalian F, Sahebkar A. Evolution of hydrogels for cartilage tissue engineering of the knee: A systematic review and meta-analysis of clinical studies. Joint Bone Spine 2021;88:105096.
5. Rahimizadeh M, Eshghi H, Shiri A, Ghadamyari Z, Matin MM, Oroojalian F, et al. Fe (HSO 4) 3 as an efficient catalyst for diazotization and diazo coupling reactions. J Korean Chem Soc 2012;56:716-719.
6. Ullah F, Othman MBH, Javed F, Ahmad Z, Akil HM. Classification, processing and application of hydrogels: A review. Mater Sci Eng C 2015;57:414-433.
7. Thakur RRS, McMillan HL, Jones DS. Solvent induced phase inversion-based in situ forming controlled release drug delivery implants. J Controlled Release 2014;176:8-23.
8. Shi X, Lin X, Yao C, Shen L, Feng Y. Injectable long-acting in situ forming systems for Radix Ophiopogonis polysaccharide. Int J Biol Macromol 2015;72:553-559.
9. Zhang L, Shen W, Luan J, Yang D, Wei G, Yu L, et al. Sustained intravitreal delivery of dexamethasone using an injectable and biodegradable thermogel. Acta Biomater 2015;23:271-281.
10. Mohammadpour F, Kamali H, Hadizadeh F, Bagheri M, Shiadeh SNR, Nazari A, et al. The PLGA microspheres synthesized by a thermosensitive hydrogel emulsifier for sustained release of risperidone. J Pharm Innov 2021:1-13.
11. Abdollahiyan P, Oroojalian F, Mokhtarzadeh A. The triad of nanotechnology, cell signalling, and scaffold implantation for the successful repair of damaged organs: An overview on soft-tissue engineering. J Controlled Release 2021;332:460-492.
12. Abdollahiyan P, Baradarn B, de la Guardia M, Oroojalian F, Mokhtarzadeh A. Cutting-edge progress and challenges in stimuli responsive hydrogel microenvironment for success in tissue engineering today. J Control Release 2020;328:514-531.
13. Abdollahiyan P, Oroojalian F, Hejazi M, de la Guardia M, Mokhtarzadeh A. Nanotechnology, and scaffold implantation for the effective repair of injured organs: An overview on hard tissue engineering. J Control Release 2021;333:391-417.
14. Colucci P, D’Angelo P, Mautone G, Scarsi C, Ducharme MP. Pharmacokinetic equivalence of a levothyroxine sodium soft capsule manufactured using the new food and drug administration potency guidelines in healthy volunteers under fasting conditions. Ther Drug Monit 2011;33:355-361.
15. Almandoz JP, Gharib H. Hypothyroidism: etiology, diagnosis, and management. Med Clin North Am 2012;96:203-221 .
16. Haynes R. Thyroid and antithyroid drugs. Pharmacological Basis of Therapeutics 1990:1361-83.
17. Hays MT. Thyroid hormone and the gut. Endocrine Res 1988;14:203-224.
18. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metab 1977;26:1-8.
19. Omidi M, Malakoutian M, Choolaei M, Oroojalian F, Haghiralsadat F, Yazdian F. A Label-Free detection of biomolecules using micromechanical biosensors. Chin Phys Lett 2013;30:068701.
20. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Fave GD, et al. Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med 2006;354:1787-1795.
21. Sachmechi I, Reich D, Aninyei M, Wibowo F, Gupta G, Kim P. Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr Pract 2007;13:345-349.
22. Zaeri S, Karami F, Assadi M. Propranolol-loaded electrospun nanofibrous wound dressing: From fabrication and characterization to preliminary wound healing evaluation. Iran J Basic Med Sci 2021;24:1279-1291.
23. Kocic I, Homsek I, Dacevic M, Grbic S, Parojcic J, Vucicevic K, et al. A case study on the in silico absorption simulations of levothyroxine sodium immediate‐release tablets. Biopharm Drug Dispos 2012;33:146-159.
24. Vita R, Saraceno G, Trimarchi F, Benvenga S. A novel formulation of L-thyroxine (L-T4) reduces the problem of L-T4 malabsorption by coffee observed with traditional tablet formulations. Endocrine 2013;43:154-160.
25. Kamali H, Khodaverdi E, Hadizadeh F, Yazdian-Robati R, Haghbin A, Zohuri G. An in-situ forming implant formulation of naltrexone with minimum initial burst release using mixture of PLGA copolymers and ethyl heptanoate as an additive: In-vitro, ex-vivo, and in-vivo release evaluation. J Drug Deliv Sci Technol 2018;47:95-105.
26. Graves RA, Freeman T, Mandal TK. In vitro dissolution method for evaluation of buprenorphine in situ gel formulation: A technical note. AAPS PharmSciTech. 2007;8:88-91.
27. Mashayekhi R, Mobedi H, Najafi J, Enayati M. In-vitro/In-vivo comparison of leuprolide acetate release from an in-situ forming plga system. Daru 2013;21:1-7.
28. Spínola V, Castilho PC. Evaluation of Asteraceae herbal extracts in the management of diabetes and obesity. Contribution of caffeoylquinic acids on the inhibition of digestive enzymes activity and formation of advanced glycation end-products (in vitro). Phytochem 2017;143:29-35.
29. Kamali H, Khodaverdi E, Kaffash E, Saffari AS, Shiadeh SNR, Nokhodchi A, et al. Optimization and in vitro evaluation of injectable sustained-release of levothyroxine using PLGA-PEG-PLGA. J Pharm Innov 2020:1-11.
30. Mohajeri SA, Yaghoubi S, Abdollahi E, Tekie FSM, Kamali H, Khodaverdi E, et al. In-vivo study of naltrexone hydrochloride release from an in-situ forming PLGA-PEG-PLGA system in the rabbit. J Drug Deliv Sci Technol 2016;36:156-160.
31. Khodaverdi E, Tayarani-Najaran Z, Minbashi E, Alibolandi M, Hosseini J, Sepahi S, et al. Docetaxel-loaded mixed micelles and polymersomes composed of poly (caprolactone)-poly (ethylene glycol)(PEG-PCL) and poly (lactic acid)-poly (ethylene glycol)(PEG-PLA): preparation and in-vitro characterization. Iran J Pharm Res 2019;18:142.
32. Kamali H, Khodaverdi E, Hadizadeh F, Mohajeri SA. In-vitro, ex-vivo, and in-vivo evaluation of buprenorphine HCl release from an in situ forming gel of PLGA-PEG-PLGA using N‑methyl‑2‑pyrrolidone as solvent. Mater Sci Eng C 2019;96:561-575.
33. Chen S, Liu W, Wan J, Cheng X, Gu C, Zhou H, et al. Preparation of coenzyme Q10 nanostructured lipid carriers for epidermal targeting with high-pressure microfluidics technique. Drug Dev Ind Pharm 2013;39:20-28.
34. Oroojalian F, Rezayan AH, Shier WT, Abnous K, Ramezani M. Megalin-targeted enhanced transfection efficiency in cultured human HK-2 renal tubular proximal cells using aminoglycoside-carboxyalkyl-polyethylenimine-containing nanoplexes. Int J pharm 2017;523:102-120.
35. McGregor C, Ali R, White JM, Thomas P, Gowing L. A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug Alcohol Depend 2002;68:5-14.
36. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Controlled Release 2002;80:9-28.
37. Kashanian S, Rostami E, Harding FJ, McInnes SJ, Al-Bataineh S, Voelcker NH. Controlled delivery of levothyroxine using porous silicon as a drug nanocontainer. Aust J Chem 2016;69:204-211.
38. Padula C, Nicoli S, Santi P. Innovative formulations for the delivery of levothyroxine to the skin. Int J Pharm 2009;372:12-6.
39. Azarbayjani AF, Venugopal JR, Ramakrishna S, Lim FC, Chan YW, Chan SY. Smart polymeric nanofibers for topical delivery of levothyroxine. J Pharm Pharm Sci 2010;13:400-410.
40. Rostami E, Kashanian S, Azandaryani A. Preparation of solid lipid nanoparticles as drug carriers for levothyroxine sodium with in vitro drug delivery kinetic characterization. Mol Biol Rep 2014;41:3521-3527.
41. Guo Q, Cao H, Li X, Liu S. Thermosensitive hydrogel drug delivery system containing doxorubicin loaded CS–GO nanocarriers for controlled release drug in situ. Mater Technol 2015;30:294-300.
42. Danafar H, Rostamizadeh K, Davaran S, Hamidi M. Drug-conjugated PLA–PEG–PLA copolymers: a novel approach for controlled delivery of hydrophilic drugs by micelle formation. Pharm Dev Technol 2017;22:947-957.
43. Danafar H, Rostamizadeh K, Hamidi M. Polylactide/poly (ethylene glycol)/polylactide triblock copolymer micelles as carrier for delivery of hydrophilic and hydrophobic drugs: A comparison study. J Pharm Invest 2018;48:381-391.
44. Alami-Milani M, Zakeri-Milani P, Valizadeh H, Salehi R, Jelvehgari M. Preparation and evaluation of PCL-PEG-PCL micelles as potential nanocarriers for ocular delivery of dexamethasone. Iran J Basic Med Sci 2018;21:153-164.
45. Venkatraman SS, Jie P, Min F, Freddy BYC, Leong-Huat G. Micelle-like nanoparticles of PLA–PEG–PLA triblock copolymer as chemotherapeutic carrier. Int J Pharm 2005;298:219-232.
46. Song Z, Feng R, Sun M, Guo C, Gao Y, Li L, et al. Curcumin-loaded PLGA-PEG-PLGA triblock copolymeric micelles: Preparation, pharmacokinetics and distribution in vivo. J Colloid Interface Sci 2011;354:116-123.
47. Khodaverdi E, Tekie FSM, Mohajeri SA, Ganji F, Zohuri G, Hadizadeh F. Preparation and investigation of sustained drug delivery systems using an injectable, thermosensitive, in situ forming hydrogel composed of PLGA–PEG–PLGA. AAPS PharmSciTech 2012;13:590-600.